APA (7th ed.) Citation

K, W., R, D., S, R., ZT, L., L, H., N, V., . . . X, L. (2023). Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO clinical and research reports, 4(8), 100533. https://doi.org/10.1016/j.jtocrr.2023.100533

Chicago Style (17th ed.) Citation

K, Wang, et al. "Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC." JTO Clinical and Research Reports 4, no. 8 (2023): 100533. https://doi.org/10.1016/j.jtocrr.2023.100533.

MLA (9th ed.) Citation

K, Wang, et al. "Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC." JTO Clinical and Research Reports, vol. 4, no. 8, 2023, p. 100533, https://doi.org/10.1016/j.jtocrr.2023.100533.